Archer R L, Cunningham A C, Moore P F, Potter J A, Bliven M L, Otterness I G
Pfizer Central Research, Groton, CT 06340.
Agents Actions. 1989 Jun;27(3-4):369-74. doi: 10.1007/BF01972825.
To investigate the potential importance of prostaglandins and thromboxane in systemic lupus erythematosus (SLE), the effects of a nonsteroidal antiinflammatory drug (piroxicam) and a thromboxane synthetase inhibitor (dazmegrel) were examined on survival, proteinuria, food consumption, body weight, and peripheral lymphocyte subset distribution in the NZB/W model of autoimmune lupus disease. The effect of an immunosuppressant (cyclophosphamide) known to be effective in the treatment of murine lupus on these parameters was also examined. Cyclophosphamide at 25 mg/kg ip weekly prolonged survival, inhibited proteinuria and prevented the characteristic decline in peripheral T cells and the relative increase in B cells seen in NZB/W lupus disease while having no apparent effect on body weight or food consumption. Neither dazmegrel at 50 or 200 mg/kg/day in the diet nor piroxicam at 2 mg/kg/day in the diet had any significant effects on these parameters.
为研究前列腺素和血栓素在系统性红斑狼疮（SLE）中的潜在重要性，在自身免疫性狼疮疾病的NZB/W模型中，检测了一种非甾体抗炎药（吡罗昔康）和一种血栓素合成酶抑制剂（达美格雷）对存活率、蛋白尿、食物消耗、体重及外周淋巴细胞亚群分布的影响。还检测了已知对治疗小鼠狼疮有效的免疫抑制剂（环磷酰胺）对这些参数的影响。每周腹腔注射25mg/kg环磷酰胺可延长生存期、抑制蛋白尿，并防止NZB/W狼疮疾病中出现的外周T细胞特征性减少和B细胞相对增加，同时对体重或食物消耗无明显影响。饮食中每日给予50或200mg/kg达美格雷以及饮食中每日给予2mg/kg吡罗昔康对这些参数均无显著影响。
